Skip to main content
MedPathMedPath Home
Clinical Trials/PACTR201008000221638
PACTR201008000221638
Other
未知

Safety and immunogenicity of a heterologous prime-bosst vaccine strategy with AdCh63 ME-TRAP and MVA ME-TRAP in healthy adults, children and infants in a malaria endemic area

Oxford University, Jenner Institute0 sites52 target enrollmentJune 15, 2010
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsMalaria

Overview

Phase
未知
Intervention
Not specified
Conditions
Malaria
Sponsor
Oxford University, Jenner Institute
Enrollment
52
Status
Other
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 15, 2010
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
Male

Investigators

Sponsor
Oxford University, Jenner Institute

Eligibility Criteria

Inclusion Criteria

  • •Consenting adult males and children aged 2\-6 years in good health

Exclusion Criteria

  • •Any of the following constitute an exclusion criterion:
  • •¿Clinically significant history of skin disorder (psoriasis, contact dermatitis etc.), allergy, symptomatic immunodeficiency, cardiovascular disease, respiratory disease, endocrine disorder, liver disease, renal disease, gastrointestinal disease, neurological illness.
  • •¿History of allergic disease or reactions likely to be exacerbated by any component of the vaccine, e.g. egg products, Kathon.
  • •¿History of splenectomy.
  • •¿Haemoglobin less than 9\.0 g/dL
  • •¿Serum creatinine concentration above \>130mmol/L
  • •¿Serum ALT concentration \>69 IU/L
  • •¿Blood transfusion within one month ofenrolment. .
  • •¿History of vaccination with previous experimental malaria vaccines.
  • •¿Administration of any other vaccine or immunoglobulin within two weeks before vaccination.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Safety of Malaria vaccines in Gambian infantsMalariaPaediatrics
PACTR201401000363170niversity of Oxford36
Completed
Not Applicable
Safety of Malaria vaccines in Gambian childreMalariaPaediatrics
PACTR201204000362870niversity of Oxford36
Recruiting
Phase 4
Safety and Immunogenicity of heterologous or homologous booster after complete vaccination against COVID-19.Covid19D012141
RBR-5y9y7p7Secretaria Municipal de Saúde do Rio de Janeiro
Recruiting
Phase 2
Immunogenicity and safety of heterologous prime boost COVID-19 vaccines in ThailandThe immune response after heterologous COVID-19 vaccine administration in healthy volunteers.COVID-19 vaccine, heterologous prime-boost, ChAdOx1, coronavac, Sinovac.
TCTR20210714003Chulabhorn Royal Academy264
Completed
Not Applicable
TRAP VAC TRIAMalariaPaediatrics
PACTR2010020001771828niversity of Oxford30